<DOC>
	<DOCNO>NCT01605825</DOCNO>
	<brief_summary>This multi-center , safety tolerability study subject chronic stable sensorimotor deficit ischemic stroke . It design double-blind , placebo-controlled , 2-period crossover study .</brief_summary>
	<brief_title>A Phase 2b Study Dalfampridine 10mg Extended Release Tablet Subjects With Chronic Deficits After Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>History stable sensorimotor deficit due ischemic stroke , confirm Investigator supportive prior image finding ( MRI/ CT scan ) ≥ 6 month poststroke Have body mass index ( BMI ) range 18.0 35.0 kg/m,2 inclusive Stable concomitant medication therapy regimen within 4 week screen visit History seizure , except simple febrile seizure Moderate severe renal impairment define calculated creatinine clearance ≤ 50 mL/minute use CockcroftGault Equation Botulinum toxin use within 2 month prior Screening Visit Orthopedic surgical procedure extremity within past 6 month Diagnosis multiple sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>